

Oncidium Foundation Expands Operations with New U.S. Subsidiary

Bringing Awareness and Enhancing Access to Radiotheranostics for Cancer Treatment

Milwaukee, USA – October 10, 2024 – The Oncidium foundation, an NGO aiming to improve global access to radioligand therapy, is pleased to announce the official launch of its U.S. subsidiary, marking a significant milestone in expanding global access to radiotheranostics. This strategic move aims to better serve U.S. people living with cancer by improving access to treatment and advancing education, while directly engaging with healthcare professionals, industry leaders, and the general public.

The Oncidium foundation's main initiative for improving patient access and raising awareness is the [RLT-Connect platform](#). This unprecedented project provides Radioligand Therapy (RLT) donations to patients, particularly in low- and middle-income countries where such treatments are not yet reimbursed. However, due to specific regulatory constraints, the program is not currently available in the U.S. As a result, the subsidiary will also explore local opportunities to support cancer patients, such as assistance with travel and accommodation during their treatments, easing the burden on patients and enhancing access.

Jean-Luc Vanderheyden, the dedicated ambassador of the U.S. subsidiary, expressed his enthusiasm for this new chapter: *“I have been in the field of nuclear medicine for nearly 44 years. It's exciting to see the progress made, particularly the potential radiotheranostics has to treat patients who previously had little hope. I am eager to bring education, hope, and new treatment possibilities to patients in the U.S., and that's what motivates me.”*

The foundation's new 501(c)(3) status enables U.S. donors to benefit from tax-deductible contributions, further reinforcing its mission to meet the needs of cancer patients nationwide. Additionally, the U.S. subsidiary will foster collaborations with local universities, companies, and healthcare organizations to accelerate the development and accessibility of innovative radiotheranostic treatments.

As part of its expansion, the foundation is also growing its local ambassador network, which currently includes over 100 ambassadors worldwide, with 8 based in the U.S. This hybrid approach focuses on both geographic outreach and specialized expertise to support the foundation's core goals.

Rebecca Lo bue, CEO of the Oncidium foundation, highlighted the importance of this new phase: *“We are excited to contribute to the growing ecosystem in the U.S. and to provide hope to people living with cancer who can benefit from radiotheranostics as a crucial tool in the fight against the disease.”*

About the Oncidium foundation:

The Oncidium foundation is a nonprofit organization dedicated to advancing global access to radioligand therapy for cancer care. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients, globally.

For more information visit <http://www.ovidiumfoundation.org>

For media inquiries, please contact: thais@ovidium-life.org